Activated Factor X - Protease-Activated Receptors Signaling Promotes Vascular Inflammation and Atherosclerosis
Project/Area Number |
26860565
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Cardiovascular medicine
|
Research Institution | The University of Tokushima |
Principal Investigator |
HARA Tomoya 徳島大学, 病院, 医員 (00644577)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | マクロファージ / 凝固因子 / 血液凝固因子 / 動脈硬化 / 炎症 / 凝固 |
Outline of Final Research Achievements |
FXa-PARs signaling participates in the development of vascular inflammation. Results of our study suggests that this signaling pathway serves as a potential therapeutic target for atherosclerosis.
|
Report
(4 results)
Research Products
(6 results)
-
[Journal Article] Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.2015
Author(s)
Hara T, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Sata M.
-
Journal Title
Atherosclerosis.
Volume: 印刷中
Issue: 2
Pages: 639-646
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
[Presentation] Rivaroxaban, a Direct Factor Xa Inhibitor, Attenuates Neointima Formation after Mechanical Vascular Injury2014
Author(s)
Tomoya Hara, Daiju Fukuda, Kimie Tanaka, Yasutomi Higashikuni, Yoichiro Hirata, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masataka Sata.
Organizer
The AHA 2014 Annual Membership Meeting
Place of Presentation
McCormick Place, Chicago (U.S.A.)
Year and Date
2014-11-17
Related Report
-
[Presentation] Rivaroxaban, a direct factor Xa inhibitor, attenuates neointima formation following vascular injury in the mouse through the inhibition of proliferative activation of vascular smooth muscle cells.2014
Author(s)
Tomoya Hara, Daiju Fukuda, Kimie Tanaka, Yasutomi Higashikuni, Yoichiro Hirata, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masataka Sata.
Organizer
ESC Congress 2014
Place of Presentation
Fira Barcelona Gran Via Conference Centre, Barcelona (Spain)
Year and Date
2014-09-02
Related Report
-
[Presentation] Rivaroxaban, a direct factor Xa inhibitor, attenuates plaque progression and destabilization in ApoE-deficient mice by inhibiting macrophage activation.2014
Author(s)
Tomoya Hara, Daiju Fukuda, Kimie Tanaka, Yasutomi Higashikuni, Yoichiro Hirata, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masataka Sata.
Organizer
ESC Congress 2014
Place of Presentation
Fira Barcelona Gran Via Conference Centre, Barcelona (Spain)
Year and Date
2014-09-01
Related Report